Top Back to top

Outcomes of Autologous and Allogeneic Stem Cell Transplantation in Patients with Hepatosplenic T-cell Lymphoma (HSTCL)

Lymphoma Working Party (LWP)
Study type:
Study number:
Type of Stem Cell Treatment:
Non-Hodgkin’s Lymphoma (NHL)
Short title:
Allo & auto SCT in hepatosplenic T-cell lymphoma
Primary objective:
The aim of this study is to evaluate the outcome of patients with HSTCL treated with alloSCT
or ASCT. The analysis would like to investigate whether there were changes in the treatment
algorithm over time which influenced the outcome of patients after transplantation. In
addition, potential risk factors for ASCT and alloSCT will be identified. Overall, this study
shall help to establish evidence-based guidelines how to integrate allogeneic and autologous
transplantation into the treatment algorithm of this rare type of lymphoma.
Key inclusion criteria:
All EBMT member countries
Principal investigator:
Imke E. Karsten
EBMT Study coordinator:
Herve Finel
Reason for processing personal data:
Patients’ data is needed to be able to identify the patient and calculate age at any time (impact on SAEs and response to clinical medications). Health care personal data is part of the CV collected for evidence of proper qualification for running the trial.
Categories of personal data collected:
Medical data already reported to the EBMT Registry
Recipients who may access the data:
Paris Study Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:

Privacy notices

Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)

Data Protection Impact Assessments

Rights available to individuals:
Data portability
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results